Literature DB >> 7138157

Reversible renal insufficiency in multiple myeloma.

S P Bernstein, H D Humes.   

Abstract

Forty-five patients met the criteria for the diagnosis of multiple myeloma in a retrospective chart review from 1975 to 1980. Renal insufficiency with peak serum creatinine concentration greater than 1.5 mg/dL involved 69% of all patients. Renal insufficiency was reversible in 55% of the cases. Treatment of hypercalcemia and/or chemotherapy for multiple myeloma was associated with reversibility in 88% of cases. Once renal insufficiency occurred in patients with multiple myeloma, those with reversible renal failure had a duration of survival fourfold longer (11.4 v 2.8 months) than those with irreversible renal insufficiency. In conclusion, reversible renal insufficiency from hypercalcemia or the myeloma process itself develops in a majority of patients with multiple myeloma. If therapy reverses the renal dysfunction, a greater life expectancy occurs. Patients with multiple myeloma and renal insufficiency should, therefore, be examined for reversible causes of renal dysfunction, since if found and treated, a substantial improvement in prognosis is achieved.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7138157

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

1.  Analysis and management of renal failure in fourth MRC myelomatosis trial. MRC working party on leukaemia in adults.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-12

2.  Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation.

Authors:  Z Q Huang; K A Kirk; K G Connelly; P W Sanders
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

3.  Pathobiology of cast nephropathy from human Bence Jones proteins.

Authors:  P W Sanders; B B Booker
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

4.  Proximal renal tubular function in myelomatosis: observations in the fourth Medical Research Council trial.

Authors:  E H Cooper; M A Forbes; R A Crockson; I C MacLennan
Journal:  J Clin Pathol       Date:  1984-08       Impact factor: 3.411

5.  Transgelin-2 in Multiple Myeloma: A New Marker of Renal Impairment?

Authors:  Karolina Woziwodzka; Jolanta Małyszko; Ewa Koc-Żórawska; Marcin Żórawski; Paulina Dumnicka; Artur Jurczyszyn; Krzysztof Batko; Paulina Mazur; Małgorzata Banaszkiewicz; Marcin Krzanowski; Paulina Gołasa; Jacek A Małyszko; Ryszard Drożdż; Katarzyna Krzanowska
Journal:  Molecules       Date:  2021-12-23       Impact factor: 4.411

6.  Renal status of multiple myeloma patients in ibadan, Nigeria.

Authors:  F A Fasola; K I I Eteng; W A Shokunbi; J O Akinyemi; B L Salako
Journal:  Ann Ib Postgrad Med       Date:  2012-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.